Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 10/20 | 0.55 |
| ▸ | MME | P08473 | 9/20 | 0.55 |
| ▸ | CPA1 | P15085 | 2/20 | 0.55 |
| ▸ | ACE2 | Q9BYF1 | 2/20 | 0.55 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.53 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31514357 | 0.92 | FOLH1 (0.58) | ACEMMECPA1ACE2FOLH1 | |
| SCHEMBL27852467 | 0.90 | MME (0.53) | ACEMMECPA1ACE2 | |
| SCHEMBL27852469 | 0.90 | MME (0.53) | ACEMMECPA1ACE2 | |
| SCHEMBL29839261 | 0.89 | BACE1 (0.47) | ACEMMECPA1ACE2FOLH1 | |
| SCHEMBL31257978 | 0.88 | OPRD1 (0.57) | ACEMME | |
| SCHEMBL30974549 | 0.86 | ACE (0.56) | ACEMMECPA1ACE2FOLH1 | |
| SCHEMBL29349965 | 0.86 | ACE (0.58) | ACEMMECPA1ACE2FOLH1 | |
| SCHEMBL29527180 | 0.85 | OPRD1 (0.58) | ACEMMECPA1ACE2FOLH1 | |
| SCHEMBL30123357 | 0.85 | ACE (0.55) | ACEMMECPA1ACE2FOLH1 | |
| SCHEMBL31415936 | 0.85 | OPRM1 (0.51) | ACEMMECPA1ACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12024571-B2 | Anti-erythropoietin receptor peptide | EPO-MED INC. (JP) | 2024-07-02 | — | — | US | disclosed |
| US-20230310539-A1 | TREATMENT OF DISEASE WITH EPOR ANTAGONIST | EPO-MED INC. (JP) | 2023-10-05 | — | — | US | disclosed |
| EP-4190345-A1 | TREATMENT OF DISEASE WITH EPOR ANTAGONIST | Epo-Med Inc. (JP) | 2023-06-07 | — | — | EP | disclosed |
| CN-116234541-A | Treatment of diseases by EpoR antagonists | EPO医药株式会社 | 2023-06-06 | — | — | CN | disclosed |
| WO-2022025204-A1 | TREATMENT OF DISEASE WITH EPOR ANTAGONIST | エポメッド株式会社 | 2022-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12024571-B2 | Anti-erythropoietin receptor peptide | EPOR, PRLHR, AVPR1A | ACE 3284/4885MME 568/4885CPA1 261/4885 |
| US-20230310539-A1 | TREATMENT OF DISEASE WITH EPOR ANTAGONIST | EPOR, PROKR1, HBZ | ACE 828/4885MME 185/4885CPA1 348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.